selected publications
-
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL.
Blood.
2023
Academic Article
GET IT
Times cited: 29 - Inhibition of Integrin αVβ3 Signaling Improves the Antineoplastic Effect of Bexarotene in Cutaneous T-Cell Lymphoma. Molecular cancer therapeutics. 2022 Academic Article GET IT
-
Phase 1 study of oral azacitidine (CC-486) plus R-CHOP in previously untreated intermediate- to high-risk DLBCL.
Blood.
2022
Academic Article
GET IT
Times cited: 23 -
Biomarker-driven management strategies for peripheral T cell lymphoma.
Journal of hematology & oncology.
2020
Information Resource
GET IT
Times cited: 30 -
CCL2/CCR2 Regulates the Tumor Microenvironment in HER-2/neu-Driven Mammary Carcinomas in Mice.
PloS one.
2016
Academic Article
GET IT
Times cited: 45 -
IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.
PloS one.
2015
Academic Article
GET IT
Times cited: 86